Stockscreener 앱 받기
2.81
0.71%
-0.02
전일 마감가:
$2.83
열려 있는:
$2.89
하루 거래량:
572.75K
Relative Volume:
0.42
시가총액:
$299.53M
수익:
-
순이익/손실:
$-134.24M
주가수익비율:
-1.5876
EPS:
-1.77
순현금흐름:
$-121.34M
1주 성능:
-8.47%
1개월 성능:
-32.61%
6개월 성능:
-52.45%
1년 성능:
-42.77%
1일 변동 폭
$2.78
$2.93
1주일 범위
$2.635
$3.17
52주 변동 폭
$2.635
$8.40
아넥손 Stock (ANNX) Company Profile
명칭
Annexon Inc
전화
(650)-822-5500
주소
1400 SIERRA POINT PARKWAY, BRISBANE
ANNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.81 | 299.53M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
아넥손 Stock (ANNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-30 | 개시 | Wells Fargo | Overweight |
| 2023-05-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-05-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | BTIG Research | Buy |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-09-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
모두보기
아넥손 주식(ANNX)의 최신 뉴스
Annexon executive sells shares worth $16,379 By Investing.com - Investing.com South Africa
Annexon chief medical officer sells $16,342 in common stock - Investing.com
Annexon EVP Ted Yednock sells $24,283 in stock - Investing.com
Annexon executive sells shares worth $16,379 - Investing.com
Annexon chief business officer sells $19,523 in company stock - Investing.com
Annexon EVP Ted Yednock sells $24,283 in stock By Investing.com - Investing.com South Africa
Annexon CFO Jennifer Lew sells shares worth $20,183 By Investing.com - Investing.com South Africa
Annexon CFO Jennifer Lew sells shares worth $20,183 - Investing.com
Annexon chief medical officer sells $16,342 in common stock By Investing.com - Investing.com UK
Annexon CFO Jennifer Lew Sells Shares to Cover Tax Obligations - TradingView
Annexon, Inc. (NASDAQ:ANNX) Short Interest Update - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Douglas Love Sells 5,021 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock - MarketBeat
Annexon EVP sells $4,260 in stock to cover tax obligations By Investing.com - Investing.com Canada
Annexon EVP Ted Yednock sells $5,331 in stock By Investing.com - Investing.com Canada
Annexon CFO Jennifer Lew sells $5,322 in stock By Investing.com - Investing.com South Africa
Annexon EVP sells $4,260 in stock to cover tax obligations - Investing.com India
Annexon CFO Jennifer Lew sells $5,322 in stock - Investing.com India
Annexon CEO Love Douglas sells $14,811 in stock By Investing.com - Investing.com South Africa
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Employee Stock Options Alert: Annexon Awards Major Equity Package Worth $1.6M - StockTitan
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Form 8-KCurrent report - br.ADVFN.com
Annexon's ANX007 Shows Significant Retinal Protection In Geographic Atrophy In Phase 2 Trial - Nasdaq
A look into Annexon Inc (ANNX)’s deeper side - SETE News
Annexon Announces Presentations Highlighting ANX007 - GlobeNewswire
Annexon Inc (NASDAQ: ANNX) Slashes -3.54%: What Could Be On The Way Going Forward? - Stocks Register
Revolutionary Eye Treatment ANX007 Preserves Vision in Geographic Atrophy Patients: Clinical Data Revealed - StockTitan
Critical Survey: Prothena (NASDAQ:PRTA) vs. Annexon (NASDAQ:ANNX) - Defense World
A stock that deserves closer examination: Annexon Inc (ANNX) - US Post News
Annexon Inc (ANNX) Shares Decline Despite Market Challenges - The News Heater
Check out these key findings about Annexon Inc (ANNX) - SETE News
Annexon Inc [ANNX] Investment Guide: What You Need to Know - Knox Daily
A year in review: Annexon Inc (ANNX)’s performance in the last year - US Post News
Market Update: Annexon Inc (ANNX) Sees Negative Movement, Closing at 3.52 - The Dwinnex
Analyzing the Impact of Earnings Reports on Annexon Inc Inc. (ANNX) Price Performance - The InvestChronicle
Annexon, Inc. (NASDAQ:ANNX) Short Interest Up 23.7% in January - MarketBeat
Annexon (NASDAQ:ANNX) and Tonix Pharmaceuticals (NASDAQ:TNXP) Head-To-Head Comparison - Defense World
What's Driving These Stocks Higher In After-hours? - RTTNews
Vanguard Group Inc's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Annexon stock touches 52-week low at $3.85 amid market challenges - Investing.com Australia
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals - MSN
Cantor Fitzgerald Estimates Annexon FY2025 Earnings - Defense World
아넥손 (ANNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아넥손 주식 (ANNX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER |
Feb 18 '25 |
Sale |
2.97 |
5,515 |
16,380 |
83,814 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 18 '25 |
Sale |
2.91 |
8,345 |
24,284 |
61,237 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 18 '25 |
Sale |
2.95 |
6,618 |
19,523 |
86,579 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 18 '25 |
Sale |
2.92 |
6,912 |
20,183 |
77,770 |
| Love Douglas | PRESIDENT AND CEO |
Feb 13 '25 |
Sale |
2.95 |
5,021 |
14,812 |
351,554 |
| Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER |
Feb 13 '25 |
Sale |
2.98 |
1,786 |
5,322 |
84,682 |
| Overdorf Michael | EVP & CHIEF BUSINESS OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,425 |
4,261 |
93,197 |
| Yednock Ted | EVP & CHIEF INNOVATION OFFICER |
Feb 13 '25 |
Sale |
2.99 |
1,783 |
5,331 |
69,582 |
0.27%
3.05%
자본화:
|
볼륨(24시간):